Tyra Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TYRA research report →
Range $29 – $56
Price Chart
About the company
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer.
- CEO
- Todd Harris
- IPO
- 2021
- Employees
- 87
- HQ
- Carlsbad, CA, US
Get TickerSpark's AI analysis on TYRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.25B
- P/E
- -8.72
- PEG
- 0.31
- P/S
- 0.00
- P/B
- 3.91
- EV/EBITDA
- -7.97
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -46.39%
- ROIC
- -44.78%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-132,762,000
- Net Income
- $-119,947,000-38.7%
- EPS
- $-2.01-33.1%
- OCF Growth
- -36.4%
- FCF Growth
- -35.3%
- 52W High
- $40.65
- 52W Low
- $12.98
- 50D MA
- $25.88
- 200D MA
- $30.51
- Beta
- 0.73
- RSI (14)
- 38
- Avg Volume
- 857.36K
No earnings-call transcripts are available for TYRA yet.
- Free Float
- 74.3%
- Shares Outstanding
- 59.66M
- Float Shares
- 44.33M
of shares held by institutions
172 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 12.20M | 0 |
| Fmr LLC | 8.92M | ▲ 1.17M |
| Jupiter Topco LLC | 4.35M | ▲ 4.35M |
| Janus Henderson Group Ltd. | 3.89M | ▲ 955.15K |
| Alta Partners Management Company, L.P. | 3.82M | 0 |
| Nextech Invest, Ltd. | 3.55M | ▼ 502.28K |
| Tcg Crossover Management, LLC | 3.25M | 0 |
| Blackrock, Inc. | 3.03M | ▲ 814.04K |
| Price T Rowe Associates Inc | 2.78M | ▲ 1.80M |
| State Street Corp | 2.14M | ▲ 924.29K |
| Commodore Capital LP | 1.88M | ▼ 600.00K |
| Paradigm Biocapital Advisors LP | 1.83M | ▼ 226.38K |
Held by 236 ETFs
Biggest fund positions in TYRA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Harris Todd | other | 864 |
| Sep 15, 26 | Rueb Yuliya | other | 2,925 |
| Sep 15, 26 | Fuhrman Alan | other | 951 |
| Sep 15, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 9,078,529 |
| Sep 9, 26 | Verjee Rehan | buy | 971.894 |
| May 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 13,160 |
| May 28, 26 | Verjee Rehan | other | 13,160 |
| May 28, 26 | Moran Susan | other | 13,160 |
| May 28, 26 | Simson Jake | other | 13,160 |
| May 28, 26 | Gulfo Adele M. | other | 13,160 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TYRA coverage
Recent articles, reports, and earnings notes.
No research on TYRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TYRA report →INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
prnewswire.com · Oct 1
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
globenewswire.com · Sep 29
Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89
defenseworld.net · Sep 25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
prnewswire.com · Sep 17
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
globenewswire.com · Sep 15
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
prnewswire.com · Sep 14
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
gurufocus.com · Sep 10
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
prnewswire.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.